|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities for emerging therapies
Datamonitor, April 2010, Pages: 243
Introduction
The commercial success of Rituxan in the treatment of NHL and Velcade and Revlimid in the treatment of MM has attracted the interest of pharmaceutical companies to these markets. There are 173 drugs in clinical development for these indications, the majority of which are molecular targeted therapies (MTTs). This contrasts with HL and MDS where there is limited pipeline activity.
Scope
-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates
-Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions
Highlights
There are currently 107 drugs in clinical development for NHL, of which 12 are in late phase development. This high R&D activity is due to the diverse nature of the diseases and the success of therapies such as Rituxan in these indications. Targeted therapies account for over half of drugs in development for NHL.
There are currently 15 drugs in clinical development for HL, of which 3 are in late phase development. Unmet needs persists in HL but are confined to relapsed patients and elderly patients, which are relatively small patient populations.
There are currently 66 drugs in clinical development for MM, of which 8 are in late phase development. MM is an incurable disease and there is a need for better and less toxic therapies across all lines of treatment.
Reasons to Purchase
-Segmentation and analysis of the current pipeline by developmental phase, drug class and company
-Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
Customers who bought this item also bought
Stakeholder Insight: Non-Hodgkin's Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth
Non-Hodgkin's Lymphoma (NHL) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Blood Cancer Drug Discoveries: what the future holds
Problem Solving in Haematology
New Approaches to the Treatment of Non-Hodgkin's Lymphoma
Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth
Multiple Myeloma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Chronic Lymphocytic Leukemia: Off-Label Prescribing Drives Market Growth
Personalized Medicine - Scientific and Commercial Aspects
|
|
|
|
